Cargando…

Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients

Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients’ baseline characteristics. Da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil-Bernal, Rosalía, González-Caballero, Juan Luis, Espinosa-Rosso, Raúl, Gómez-Gómez, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206070/ https://www.ncbi.nlm.nih.gov/pubmed/34131191 http://dx.doi.org/10.1038/s41598-021-91912-x

Ejemplares similares

Tuning the Adhesive Properties of Soy Protein Wood Adhesives with Different Coadjutant Polymers, Nanocellulose and Lignin
por: Podlena, Milan, et al.
Publicado: (2021)

Probiotic Monotherapy with Lactobacillus reuteri (Prodentis) as a Coadjutant to Reduce Subgingival Dysbiosis in a Patient with Periodontitis
por: Salinas-Azuceno, Claudia, et al.
Publicado: (2022)

Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis
por: Cruz-Gomez, Álvaro J., et al.
Publicado: (2021)

Myeloproliferative neoplasms in five multiple sclerosis patients()
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2013)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Preferences Toward Attributes of Disease-Modifying Therapies: The Role of Nurses in Multiple Sclerosis Care
por: del Río-Muñoz, Beatriz, et al.
Publicado: (2022)

Performance validity in outpatients with multiple sclerosis and cognitive complaints
por: Nauta, IM, et al.
Publicado: (2021)

Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis
por: Sipilä, Jussi OT, et al.
Publicado: (2023)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis
por: Lleixà, Cinta, et al.
Publicado: (2023)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Impact of reflex locomotion and the Bobath concept on clinical and biomolecular parameters in people with multiple sclerosis: study protocol for a randomized controlled trial
por: Abreu-Corrales, Aymara, et al.
Publicado: (2023)

Preference-based Health status in a German outpatient cohort with multiple sclerosis
por: Reese, Jens Peter, et al.
Publicado: (2013)

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019)

Virtual Rehabilitation for Multiple Sclerosis Using a Kinect-Based System: Randomized Controlled Trial
por: Lozano-Quilis, Jose-Antonio, et al.
Publicado: (2014)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Hereditary multiple exostoses and schizophrenia
por: Gòmez-Bernal, Germán
Publicado: (2008)

Modifiable Risk Factors for Increased Arterial Stiffness in Outpatient Nephrology
por: Elewa, Usama, et al.
Publicado: (2015)

The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis
por: Benítez-Fernández, Rocio, et al.
Publicado: (2022)

An Entropy Approach to Multiple Sclerosis Identification
por: Perez, Gerardo Alfonso, et al.
Publicado: (2022)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Renal neoplasms in tuberous sclerosis mice are neurocristopathies
por: Unachukwu, Uchenna, et al.
Publicado: (2021)

Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
por: Sancho-Saldaña, Agustín, et al.
Publicado: (2022)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Feeding the gut microbiome: impact on multiple sclerosis
por: Bronzini, Matteo, et al.
Publicado: (2023)

Endoscopic Submucosal Dissection for Gastric Neoplasm at an Outpatient Clinic: Efficacy and Safety
por: Jung, Hwoon-Yong, et al.
Publicado: (2014)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

Differential cognitive impairment for diverse forms of multiple sclerosis
por: Gonzalez-Rosa, Javier J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_a7v6r64mgkv3nhfodoj85hcfc1